A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients
- Conditions
- Hypertension
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2013-11-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1109
- Registration Number
- NCT00240448
- Locations
- 🇺🇸
Christopher Chappel, MD, Kissimmee, Florida, United States
🇺🇸Attention: Larry I. Gilderman, D.O., Pembroke Pines, Florida, United States
🇺🇸Treasure Valley Cardiology, Boise, Idaho, United States
Randomized Single-blind Placebo Controlled Comparative Trial of Pramipexole and Bromocriptine in Parkinson's Disease
- Conditions
- Parkinson Disease
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2013-11-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 208
- Registration Number
- NCT00240409
- Locations
- 🇨🇳
First Hospital of Beijing University, Beijing, China
🇨🇳Beijing Hospital, Beijing, China
🇨🇳Peking Union Medical College Hospital, Beijing, China
A Comparison of Telmisartan + Hydrochlorothiazide With Amlodipine + Hydrochlorothiazide in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension (ATHOS Study)
- Conditions
- Hypertension
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1000
- Registration Number
- NCT00240474
- Locations
- 🇫🇮
Hämeenlinnan lääkäriasema Oy, Linnan klinikka, Hämeenlinna, Finland
🇫🇮Kouvolan lääkäriasema, Kouvola, Finland
🇫🇮Hatanpään terveyskeskussairaala, Tampere, Finland
12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 491
- Registration Number
- NCT00240435
- Locations
- 🇨🇦
St. Boniface General Hospital, Winnipeg, Manitoba, Canada
🇺🇸University of California - Los Angeles, Los Angeles, California, United States
🇨🇦Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada
Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2Hypertension
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2013-11-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 96
- Registration Number
- NCT00240422
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site, Nürnberg, Germany
🇩🇪Friedrich-Alexander-Universität, Erlangen, Germany
🇩🇪Universität Erlangen-Nürnberg, Nürnberg, Germany
Spiriva (Tiotropium Bromide) Assessment of FEV1 - (SAFE-Portugal).
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 311
- Registration Number
- NCT00239408
- Locations
- 🇵🇹
Hospital Garcia de Orta, Almada, Portugal
🇵🇹Unidade Funcional de Infecciologia, Barreiro, Portugal
🇵🇹Hospital Distrital de Faro, Faro, Portugal
Telmisartan80/HCTZ25 Versus Telmisartan80/HCTZ12.5 in Hypertension Not Responding to Telmisartan80/HCTZ12.5
- Conditions
- Hypertension
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 713
- Registration Number
- NCT00239369
- Locations
- 🇫🇷
Hopital Avicenne, Bobigny, France
🇨🇳Boehringer Ingelheim Investigational Site, Taipei, Taiwan
🇫🇷Mg Recherches, Paris, France
Efficacy and Safety (Including 24-hour Holter Monitoring) of Tiotropium Inhalation Capsules in Patients With COPD
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 196
- Registration Number
- NCT00239460
- Locations
- 🇺🇸
Attn: William C. Bailey, M.D., Birmingham, Alabama, United States
🇺🇸Boehringer Ingelheim Investigational Site, Houston, Texas, United States
🇺🇸The Oregon Clinic, Portland, Oregon, United States
12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 429
- Registration Number
- NCT00239473
- Locations
- 🇨🇭
Ospedale San Giovanni, Bellinzona, Switzerland
🇨🇭Kantonsspital St. Gallen, St. Gallen, Switzerland
🇮🇹Ospedale Silvestrini, San Sisto (pg), Italy
A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 605
- Registration Number
- NCT00239421
- Locations
- 🇦🇹
Med. Uni.-Klinik Graz, Graz, Austria
🇩🇰Lungemedicinsk Forskning 2B, Aarhus, Denmark
🇩🇰Bispebjerg Hospital, Copenhagen NV, Denmark